News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Diabetes, Infectious Diseases Early Focus of San Antonio Biomed Plan

David Holley, Xconomy Texas —  San Antonio — [Updated 12/14/17, 11:54 p.m. See below.] ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
GenSpera Inc. secures more than $3 million from investors
May 29, 2014

By W. Scott Bailey, San Antonio Business Journal

GenSpera Inc. (OTCQB:GNSZ) has entered into definitive agreements with investors who are purchasing approximately $3.33 million worth of the San Antonio-based biotech company's common stock and warrants through a registered public offering.

Each unit sold consists of one share of common stock, one-half of a Series A warrant, one Series B warrant and one Series C warrant. The Series A warrants will be exercisable into approximately 2.1 million shares of GenSpera's common stock at a price of $1.15 per share.

The Series B warrants will be exercisable into approximately 4.2 million shares of the company's common stock at a price of $0.85 per share. And the Series C warrants will be exercisable into approximately 4.2 million shares of the company's common stock at an exercise price of $0.85 per share.

The offering is expected to close on or about June 3.
I reported in March that GenSpera had filed a registration with the U.S. Securities and Exchange Commission for a public offering.

GenSpera is in the research-and-development phase for its lead drug, G-202, which could be used to treat a variety of cancers. The company is currently conducting Phase II clinical trials for G-202.

 

Stay informed. Subscribe to BioMed SA news alerts.